Clinical Edge Journal Scan

Early gastric cancer: Undifferentiated-predominant mixed-type is more aggressive


 

Key clinical point: Patients with undifferentiated-predominant mixed-type (MU) early-stage gastric cancer (EGC) had a higher risk for submucosal invasion and lymph node metastasis vs. pure undifferentiated-type (PU) EGC.

Major finding: Patients with MU vs. PU EGC had a significantly higher risk for submucosal invasion (odds ratio [OR] 2.19; 95% CI 1.90-2.52) and lymph node metastasis (OR 2.28; 95% CI 1.72-3.03). There was no difference in the risk for lymphovascular invasion in patients with MU vs. PU EGC (OR 1.81; 95% CI 0.84-3.87).

Study details: This article was a meta-analysis of 12 observational studies including 5644 patients with early gastric cancer.

Disclosures: This study was sponsored by the International Science and Technology Cooperation Fund of Changzhou, China, Young Medical Talents of Jiangsu Province, Changzhou Special Fund for Introducing Foreign Talents, and others. The authors declared no competing interests.

Source: Yang P et al. Undifferentiated-predominant mixed-type early gastric cancer is more aggressive than pure undifferentiated type: a systematic review and meta-analysis. BMJ Open. 2022;12:e054473 (Apr 7). Doi: 10.1136/bmjopen-2021-054473

Recommended Reading

Live-donor liver transplants for patients with CRC liver mets
MDedge Hematology and Oncology
New Barrett’s esophagus guideline reduces reliance on endoscopy
MDedge Hematology and Oncology
Two rounds of FIT vs. single colonoscopy as a one-time CRC screening
MDedge Hematology and Oncology
Global incidence, deaths from CRC doubled over past 3 decades
MDedge Hematology and Oncology
Better survival in older cancer patients who take metformin
MDedge Hematology and Oncology
PD-L1 test debated in gastroesophageal cancer immunotherapy
MDedge Hematology and Oncology
Gastric cancer: Function-preserving surgery fails to show noninferiority
MDedge Hematology and Oncology
HER2-negative gastric cancer: Docetaxel-based chemotherapy does not improve outcomes
MDedge Hematology and Oncology
Gastric cancer: Add-on apatinib to neoadjuvant chemotherapy shows good response
MDedge Hematology and Oncology
Gastric cancer: Perioperative capecitabine plus oxaliplatin shows good survival
MDedge Hematology and Oncology